

## Special Issue

# Decision-Making Biomarkers in the Treatment of Hepatocellular Carcinoma

### Message from the Guest Editors

In recent years, significant progress has been made in the treatment of hepatocellular carcinoma (HCC). With the introduction of various therapeutic options, selecting the optimal treatment strategy for each patient has become increasingly important. However, there is still insufficient evidence to determine whether conversion surgery improves long-term prognosis. This SI aims to present the latest research findings, from basic science to clinical applications. Topics include the prediction of disease progression using research biomarkers, the evaluation of relapse risk, and prognostic biomarkers, alongside established clinical tools such as blood biochemistry and imaging.

---

### Guest Editors

**Dr. Norihiro Imai**

Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, Nagoya, Japan

**Dr. Dongming Liu**

Department of Hepatobiliary Cancer, Liver Cancer Research Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, National Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin, China

---

### Deadline for manuscript submissions

30 September 2026



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/237180](https://mdpi.com/si/237180)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)